In recent years, with the advancement of molecular pathology and tumor microenvironment research, biomarkers such as cytokeratin 19 (CK19), Ki67 antigen (Ki67), and β-catenin have gradually become key targets for analyzing HCC heterogeneity, invasiveness, and recurrence risk. The gene discussed is MKI67; the disease is neoplasm.